Natera files suit against ArcherDX for Patent Infringement

Natera files suit against ArcherDX for Patent Infringement

Monday, 27 January 2020

      

Natera, Inc. a global leader in cell-free DNA testing, filed suit against ArcherDX for infringement of Natera’s U.S. Patent No. 10,538,814. The  complaint was filed in the U.S. District Court of Delaware.

The ‘814 patent is titled “Methods for Simultaneous Amplification of Target Loci” and was issued by the United States Patent and Trademark Office (“USPTO”) on January 21, 2020. The ‘814 patent claims methods for using multiplex polymerase chain reaction (“multiplex PCR”) technology to simultaneously amplify multiple nucleic acid regions of interest in a single reaction before using high-throughput sequencing to characterize the nucleic acids. The ‘814 patent is one of more than 200 patents issued or pending in Natera’s global intellectual property portfolio, including more than 60 in the field of oncology.

All these negatives with normal https://www.unica-web.com/archive/2015/english/GA2015-minutes-2.html tadalafil 40mg pharmaceutical treatment usually make people seek help elsewhere. unica-web.com cialis in australia So, it is time to infuse life in your bedroom again. The biggest brand, get viagra from india and its counterpart viagra or sildenafil citrate enhance the blood circulation and flow into the male organ and facilitate the man to have an erection for a longer period of time. You can ask your online friends about their experiences, and share yours too. cheap viagra order

Natera’s complaint alleges that ArcherDX’s sale and use of certain cell-free DNA-based oncology products infringes on the ‘814 patent. ArcherDX has introduced oncology products using multiplex PCR technology, including a tool for personalized cancer monitoring. Natera has the exclusive rights to perform and license personalized monitoring and MRD testing in oncology using its patented multiplex PCR technology. Natera is seeking injunctive relief and monetary damages.

“Natera will enforce its intellectual property rights and will stop unlicensed use of its patented technology in the field of minimal residual disease and personalized cancer monitoring,” said Gary Frischling from the law firm Milbank LLP, Natera’s counsel in the matter.

[huge_it_slider id=”15″]

Key Facts


News Category Legal And Regulatory
Company ArcherDx Inc
Natera Inc
Country North America > United States of America

Source: Company Press Release

Leave a Reply

Your email address will not be published. Required fields are marked *

86 − = 82